Endocrine disrupting chemicals (EDCs) are pollutants found throughout the environment that disrupt normal endocrine processes. In mice, penis development is thought to be most susceptible to EDCs during a critical developmental window occurring on embryonic days (E) 15.5-17.5. However, androgen signaling begins on E13.5 when androgen receptor (AR) protein is found in the genitalia and testosterone is circulating. We hypothesize that disrupting androgen signaling prior to the established critical window sensitizes the penis to future androgen disruption. To test this hypothesis, CD1 dams were exposed to vinclozolin or a corn oil solvent control on E13.5 and E14.5 and AR levels were measured with immunohistochemistry on E14.5. Early antiandrogen exposure reduced AR within nuclei and decreased intensity of AR expression within E14.5 genitalia. To evaluate the influence of antiandrogen exposure before the known critical window of penis development, two groups of pregnant dams (n = 3) were exposed to vinclozolin starting at either E13.5 or E14.5 and continued exposure through E16.5. Histology and M.O.U.S.E. scoring were used to quantify penis abnormalities. To account for differences in total doses mice experienced due to differences in length of dosing time, we compared animals that received the same total doses. Exposure to antiandrogens on E13.5 exacerbated malformations when exposure was continued through sexually dimorphic development. Both exposure time and vinclozolin dose are important for severity of vinclozolin-induced penis abnormalities in mice. This work shows that antiandrogen exposure prior to sensitive periods can exacerbate the effects of later antiandrogen exposure on reproductive development.
Introduction
Endocrine disrupting chemicals (EDCs) are prevalent pollutants in water, air, and soil, and are correlated with increased risk of birth defects across the globe [1] [2] [3] [4] [5] . EDCs are consumed through inhalation, drinking water, skin contact, and food consumption. Many EDCs have estrogenic or antiandrogenic properties that disrupt C The Author(s) 2018. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 639 endogenous sex hormone signaling. Fetal development and sexual differentiation are strongly affected by EDCs, especially when exposure occurs during the critical developmental time window during which steroid hormone signaling is driving differentiation of sexually dimorphic organs [6] . For example, it is well known that androgen receptor (AR) is the apex of a regulatory hierarchy that drives sexual differentiation of the external genitalia [7] , but these effects depend on developmental stage. Mice exposed to high doses of antiandrogenic EDCs during staggered dosing days have different rates of hypospadias incidence (a congenital penis deformity common in humans). Exposure to antiandrogens on embryonic day (E) 15.5 and E17.5 induces the strongest abnormalities in external genital development in mice and rats, respectively [8, 9] . Exposures to EDCs on E13.5 alone or E12.5-E13.5 induce very few hypospadias cases [8, 10] . Such critical windows of development define when a tissue is most dependent on endocrine signaling and most sensitive to endocrine alterations. The tissues, however, must be organized and made competent to respond to hormones during the critical window. For example, sex steroid signaling organizes the fetal brain to respond to future endocrine signals [11, 12] . Also, zebrafish developmentally exposed to environmental estrogens show a stronger response to environmental estrogens later in development [13] . Here, we propose that early antiandrogen exposure, prior to the critical window within which the genitalia is known to be androgen sensitive, can exaggerate the effects of later EDC exposure by altering AR expression (organization).
In the mouse, external genital development starts on E9.5, and proceeds similarly in both males and females to form a bipotenital genital tubercle [14] . On E13, fetal Leydig cell differentiation is complete within the testes, and they begin to secrete androgens. These androgens are released into the circulation and bind to ARs in the genital tubercle and initiate a complex cascade of molecular events that masculinize the external genitalia [15] . These cascades are believed to be the strongest during the critical window within which the genitalia are most sensitive to androgen signaling disruption (e.g. E15.5 in the mouse). AR mRNA, however, has been detected within the genitalia prior to androgen production at E11.5, and protein levels are detectable with immunohistochemistry in the urethral epithelium on the day that androgens are synthesized, E13.5 [10] . Although AR protein expression is low at E13.5, with females and males expressing similar amounts of AR [10] the necessary elements for androgen signaling are present prior to the critical window. By E15.5 AR is sexually dimorphic, and is higher in males than females [10] , and disruption of AR signaling at this time can "feminize" the genitalia. The ways in which the dimorphism in AR protein quantity becomes established are not well studied.
The development of the penis is a complex process that involves endodermal, mesodermal, and ectodermally derived cells [16] . All of the resulting tissue types coordinate with each other to induce normal development. Indeed, hypospadias is consistently associated with other de-masculinized phenotypic endpoints [17, 18] . In both humans and rodents, the urethra is proximally located and with time the urethral exit migrates up the shaft of the penis as if it is being zipped up [19, 20] . In the rodent model, urorectal septation, proximal urethral opening (PUO), urethral length, and preputial swelling hypoplasia are all associated with urogenital feminization and hypospadias [14, 19, 21] . In males, the PUO completely closes and the urethral epithelium is septated from the ectodermal epithelium, which results in a tubularized, distally exiting urethra [22] . As this is happening the preputial swellings expand and wrap around the glans penis. The presence of a PUO in either sex after E16.5 is indicative of abnormal genital development. Several studies show that the incidence of hypospadias in mice is strongly correlated with antiandrogenic EDC dose, with higher doses resulting in higher hypospadias rates [23, 24] . The molecular mechanisms that are driving the increase in hypospadias severity or controlling variation of hypospadias severity remain elusive. Indeed, hypospadias severity in humans is highly variable [25] , and understanding the factors that lead to reduced severity will help us develop ways to protect the developing fetus [26] . Here, we test the hypothesis that blocking androgen signaling, prior to established critical window of penis development (E15.5-E16.5), but when AR and testosterone are present, leads to disrupted development of the male external genitalia. To test this hypothesis, we used a model antiandrogen (vinclozolin) to block AR signaling 1 or 2 days before the developmental window within which the genitalia become sexually dimorphic and examined AR levels in the penis and the downstream morphological consequences of this early antiandrogen exposure.
Material and methods

Mouse maintenance and treatment
All studies were carried out under an approved protocol established by East Carolina University (ECU) Institutional Animal Care and Use Committee (AUP D-297). Eight-week-old CD-1 mice were purchased (Charles River Breeding Laboratories Raleigh, NC) and acclimated for at least 7 days to 70-72
• F on a 12-h light-dark cycle with free access to food and water (Purina ISOCHOW). CD1 mice were time mated by setting one to two female mice with a male mouse. Vaginal plugs were checked each morning during the hours of 8:00-10:00 am. The presence of a vaginal plug indicated mating had occurred and the dam was recorded as being E0.5 at noon that day. Pregnant dams were removed from the male's cage and were housed with same treatment dams or singingly. Vinclozolin (Sigma Aldrich, St. Louis, MO,45705), a model antiandrogenic endocrine disrupting pesticide, and its metabolites are known to competitively inhibit the ability of androgen to bind to AR and have been used to consistently induce hypospadias in previous studies [27] [28] [29] . Vinclozolin is used in this study to block the AR [26, 30, 31] to test whether early blockade of androgen signaling alters later AR levels and androgen-dependent development. The selected doses were expected to give consistently high rates of hypospadias, but at different severities. The range of penis abnormities allows for severity comparisons within and among the two dose-response curves (early vs later exposure times). Vinclozolin doses 15, 20, 25, or 30 mg of vinclozolin were dissolved in 0.5 mL of Tocopherol stripped corn oil (Millipore, Santa Ana, CA, 02901415) for doses 75, 100, 125, 150 mg/kg, respectively. The mixture was heated at 60
• C and mixed with a Genemate Rotator (H-6800) for 3 h. Dose volume (μL) received by the pregnant dam was 2.5 multiplied by the weight of the pregnant dam.
Does early antiandrogen exposure affect androgen receptor levels?
Time mated pregnant dams were orally gavaged with 125 mg/kg of vinclozolin dissolved in Tocopherol stripped corn oil, or the Tocopherol stripped corn oil solvent control on E13.5 and E14.5 (n dam = 3, N pup = 6) between the hours of 11:30 and 13:30. This dose of vinclozolin is known to consistently induce hypospadias when given during the critical window of development when genitalia become sexually dimorphic (E15-E16) [26] . One hour after final dose on E14.5, dams were euthanized. Genitalia were collected Figure S1 ) were labeled and imaged at the same time as the experimental samples. Negative control images are pictures of control males in the ventro-proximal region of the external genitalia where AR concentrations are highest. These negative control slides were not incubated with primary antibodies, but were incubated with the same concentration of secondary antibodies as the sample slides. The tissue was rinsed and washed three times between steps with 1X phosphate-buffered saline with 1% Tween (Bio-Rad, Hercules, CA, 1706531) (Supplemental Protocol 1). To eliminate interassay variation, all replicate samples were immunohistochemically processed, imaged (Zeiss LSM 700 confocal microscope ×40 lens; numerical aperture 1.3), and analyzed at one time. For each individual, the mesenchyme at the base of the genitalia one section before the PUO was identified. Brightness was assessed across all samples with the brightest sample being used to set exposure parameters. All samples were imaged and compared using the same thresholds and exposure times, and since these settings were based on the brightest sample no sample was overexposed. The observer that collected the AR data was blind to treatment, and data were collected from slides in random order. To randomize samples, samples were numerically ordered based on dam and pup number and random numbers were generated using the function sample() (in R statistical programing environment), and assigned to each sample in order. Images were then renamed based on their random number assignment, and reordered so that the random numbers were numerically ordered. Each image was then opened in numerical order and a grid of 1.4 × 1.4 μm bounding boxes was generated using the Image J grid function. All bounding boxes located in the mesenchyme were counted and assigned a numerical identifier, and random numbers were generated based on the total number of available bounding boxes. Bounding boxes with the numerical identifier that corresponded to the first four random numbers were selected for sampling. For each of the selected bounding boxes, the total number of nuclei (DAPI positive) and number of nuclei that were positive for AR (488 positive) were numbered and counted.
Next, to evaluate intensity of AR labeling nine nuclei were randomly selected from the total number of nuclei across all four bounding boxes for each individual. With the numbered nuclei identified, random numbers were generated using sample() for the total nuclei present across all four bounding boxes, and the nuclei corresponding to the first nine numbers were selected for evaluation. To evaluate intensity we opened the original czi image file in Zen Blue which was produced during confocal processing using a Zeiss 700 laser scanning microscope. We identified each randomly selected nuclei and measured the intensity of the AR expression using the spline function. Intensity is defined as:
gray values in 488 channel number of pixels Does early antiandrogen exposure affect later penis morphogenesis? Dose response
To test if blocking early AR signaling prior to the known sensitive window of penis development exacerbates responses to antiandrogens given during the critical window, time mated pregnant dams were assigned to one of two dosing windows, E13.5-16.5 or E14.5-16.5. Fifteen dams were randomly assigned to one of five doses of vinclozolin (n = 3) 0, 75, 100, 125, or 150 mg/kg for the first and second dosing windows and were orally gavaged once per day between the hours of 11:30 and 13:30. We randomized dosing schedules by giving the treatments numerical identifiers, for example, Corn oil = 1, Vinc dose 75 mg/kg = 2 etc. then we generated random numbers and assigned dams to treatments based on those numbers.
We had a total sample size of 30 dams (5 treatments × 2 dosing windows × 3 replicate dams), and nested within these 30 dams were 151 embryos (see Supplemental Table S2 for more detail).
Day vs. dose comparisons
The dosing windows in this experiment were separated by 1 day. This means that E13.5-E16.5 dosing window receives one addition day of treatment. Animals in the same treatment and longer dosing window (E13.5-E16.5) experienced a higher cumulative dose of vinclozolin. Therefore, any effects ascribed to early exposure could be due to increased total cumulative dose. Our dosing regimen described above provided one dose that could be used to compare total dose across the different dosing windows to test for an effect caused by length of dosing times. Specifically, the 75 mg/kg dose over 4 days is equivalent to 100 mg/kg over 3 days (300 mg/kg). Importantly, however, we also tested if the early exposure (beginning on E13.5) or the cumulative dose was more important at higher doses by assigning an independent set of pregnant dams (N = 3) in the E14.5-16.5 dosing window to a 200 mg/kg dose (600 mg/kg total dose) which was compared to the 150 mg/kg dose given over the 4-day E13.5-16.5 dosing window (Table 1 ). This dose (200 mg/kg) was intentionally included in the design so that we had two cumulative doses that overlap which allowed for direct comparisons between time of exposure and total dose. The 200 mg/kg dose was left out of the daily dose analyses because it did not overlap with the other doses.
To eliminate variation in developmental stage caused by potential differences in day of birth, dams were euthanized on E18.5 between the hours of 11:30 and 13:30, fetuses were removed, and the sex of the pups was determined by examining the gonads, which are not affected morphologically by these doses at this particular exposure time window [26] . Hypospadias presence and severity can be precisely and accurately staged at this time period [26] . Developmental stage (E18.5) of the embryo was verified by morphological evaluation using the Theiler staging system (stage 26) [32] . Phenotype of mice did vary within Theiler stage 26, but were never 1 stage greater or less than Theiler stage 26; therefore, all mice were considered the same stage for analyses. Genitalia from all mice were removed and stored in 10% neutral buffered formalin (Richard Allan Scientific, San Diego, CA, 5700TS) until processing.
Histology and morphological data collection
All external genitalia were imaged and the severity of hypospadias was scored using the M.O.U.S.E. protocol [26] . Genitalia were then dehydrated through a graded series of ethanol baths, cleared with slide bright (xylene substitute; Newcomer Supply, ABSB-04), and infiltrated and embedded in paraffin wax (Paraffin X; Newcomer Supply, 6534) [33] (Supplemental Protocol 2). Genitalia were serially sectioned perpendicular to the proximal to distal axis of the penis (10 μm) and then stained with hematoxylin (Newcomer Supply, 1201) and eosin (Newcomer Supply, 1072) and microscopically evaluated. A combination of ×100 and ×200 objectives on the Leica DME microscope was used to identify and define relevant histological landmarks. The length of the genitalia, urethral length, and height of the PUO and urethra septation height were all collected for analysis ( Figure 1 ). The base of the penis was defined as the first section where the genitalia was disconnected from the perineum, and was established as the first section for data collection. The height of the genitalia was then calculated as the sum of all the sections between the base of the penis and the distal tip multiplied by the section thickness of 10 μm (Figure 1) . Likewise, the urethral length was determined by counting the number of sections, from the base to the first section where the urethra opened to the external environment multiplied by section thickness (Figure 1) . Next, the presence and height of the PUO were measured (Figure 1 ). Septation height was collected as the number of sections that had a urethra separated from the ventral epithelium of the penis. Septation width, the space between the centralized urethra and ventral epithelium, was measured on the slide identified as the base of the penis at ×200 with a calibrated reticule (Figure 1 ).
Statistical analysis
All data were analyzed in R statistical programming environment v. 3.4.3 [34] (Supplemental R code). Dose response and cumulative dose were analyzed with the lme4 package [35] . To avoid pseudoreplication, dam was treated as a random effect in all models with pups being nested within dam [36] . Total number of pups analyzed per treatment × dosing window regimen are displayed in Supplemental Table S2 . Assumptions of homoscedasticity, normality, and dispersion were tested by interpreting residual plots, qqplots, and dispersion coefficients, respectively. One dam from the E13.5-16.5, 125 mg/kg group was removed from the analysis due to poor maternal health. The dam underwent gavage stress during the dosing window and lost weight during pregnancy. Pups had severe hypospadias and severe defects in other penis morphological endpoints. They were removed from analysis because they incurred additional stress that pups from other dams did not incur, which we believe exacerbated the effect of vinclozolin. After outlier removal, this treatment group had a total of 19 and 16 pups analyzed for hypospadias quantification and histology respectively (nested in two dams). The mean density of nuclei with AR present and AR intensity were analyzed with a normal error distribution. PUO incidence, septation incidence, and hypospadias incidence were analyzed using a mixed model binomial regression. PUO height and septation data were analyzed as raw counts of 10 μm histological sections; therefore, a regression was performed using a Poisson error distribution. A Poisson error distribution was used to phenomenologically describe the relationships between dose, exposure window, and the Downloaded from https://academic.oup.com/biolreprod/article-abstract/99/3/639/4970759 by OUP site access user on 04 October 2018 response. Penis length was used to allometrically correct for urethral length as previously described [26] . Septation width, was collected using the eyepiece micrometer, was analyzed with a normal distribution, as the measurements were continuous. Hypospadias severity score (M.O.U.S.E.) proportionally scales with urethral length [26] and is on an interval scale. Hypospadias severity was analyzed with a normal error distribution using linear mixed models. Nested models included the variables daily dose or cumulative dose and dosing window and were compared with likelihood ratio tests (LRT) using P < 0.05 to establish the best model fit [36] . Cumulative dose was determined by multiplying total days dosed by the daily dose. Daily doses were treated as regression analyses, while total doses were analyzed in an ANOVA framework. This allowed us to investigate if severity difference were truly driven by day of exposure, the total dose received, or their interaction. Linear mixed effects models were used for all cumulative dose analyses with dam treated as a random effect. For each response, models were compared with LRT using P < 0.05 to select the best model. Cumulative doses 300 and 600 mg/kg were used to test if embryonic day was significant.
Results
Androgen receptor is diminished by early vinclozolin exposure
To test if vinclozolin exposure, prior to the window within which the penis morphogenesis is most sensitive, disorganized AR signaling, we used immunofluorescence to quantify the number of cells expressing AR and quantified the intensity of expression. Mice exposed to vinclozolin on E13.5 and again for 1 h on E14.5 (n dam = 3, N pup = 6) had diminished density of nuclei expressing AR in the ventro-proximal region of the mesenchyme when compared to corn oil controls ( Figure 2C , df = 1, χ 2 = 9.1128, LRT P = 0.000269) on E14.5. Further those cells that expressed AR in the vinclozolin exposed animals had greatly decreased intensity of nuclear AR expression in the ventro-proximal mesenchyme relative to corn oil controls ( Figure 2D , df = 1, χ 2 = 13.274, LRT P = 0.002538).
Early vinclozolin exposure potentiates continued antiandrogen exposure
To test the developmental implications of pre-critical window reductions in AR nuclear density, we exposed mice to either E13.5-16.5 or E14.5-E16.5 dosing window. No differences in litter size and mass were observed in any of the treatment groups (LRT P > 0.05; Supplemental Table S3 ). Only sex differences in mass were observed with males being 0.05821 g more than females (df = 1, χ 2 = 24.0968, LRT P = 9.094e-07; Supplemental Table S3 ). Both dosing windows displayed dose-dependent reductions in masculinization of the external genitalia, but when vinclozolin exposure began on E13.5 penis morphology was more strongly affected relative to when dosing began on E14.5 (Figures 3-5) . We found that vinclozolin exposure beginning on E13.5 led to an interaction between day and dose for hypospadias incidence (n dam = 3, N pup = 182, Figure 4A , df = 1, χ 2 = 6.9016, LRT P = 0.008612)
where day of exposure affected the dose response. Both dose and day were significant in the dose response for M.O.U.S.E. [26] severity score (n dam = 3, N pup = 182, Figure 4B , df = 1, χ 2 = 15.7618, LRT P = 7.184e-5), but there was not interaction between dose and day. PUO incidence showed an additive change in the dose response between the two dosing windows (n dam = 3, N pup = 151, Figure 5A , df = 1, χ 2 = 23.0058, LRT P = 1.615e-6). PUO height and septation height showed an interaction between dose and exposure day (n dam = 3, N pup = 151, Figure 5B , df = 1, χ 2 = 4.1196, LRT P = 0.04239) (n dam = 3, N pup = 151, Figure 5B , df = 1, χ 2 = 12.395, LRT P = 0.0004305) and urethral length, corrected for penis length, Binomial and linear regressions were used for hypospadias incidence and severity data, respectively. Likelihood ratio tests were used to select the best model and a P-value < 0.05 was used to assess significant parameters in the model. Shaded envelopes are 95% confidence intervals derived from model estimates, ndam = 3, Npup = 182.
showed no interaction, but a significant difference in dose and day of exposure in the dose response (n dam = 3, N pup = 151, Figure 5D , df = 1, χ 2 = 12.5717, LRT P = 0.0003916). Depending on the endpoint measured, the timing of exposure either showed an interaction between the dose received and exposure window meaning there was a change in the dose response, or day and dose were significant with E13.5-16.5 inducing more severe affects.
Timing of exposure impacts penis abnormalities
To explicitly test whether exposure on day E13.5 or total dose was driving the increased strength of the vinclozolin dose response recorded for the E13.5-16.5 dosing window, we evaluated penis morphology in individuals that received identical total doses of vinclozolin over the different dosing times (Table 1) . Embryonic day significantly impacted penis morphology ( Figure 6 ). Hypospadias severity (n dam = 3, N pup = 85, Figure 6A The effect induced by vinclozolin exposure beginning on E13.5 was larger at 300 mg/kg cumulative dose than 600 mg/kg for all endpoints except septation. Animals in a cumulative dose of 300 mg/kg and dosed on E13.5-16.5 had 60.26% higher hypospadias severity, 64.33% decrease in septation height, and 13.35% decrease in urethral length relative to those dosed on E14.5-16.5. Individuals receiving a cumulative dose of 600 mg/kg on E13.5-16.5 experienced a 22.48% increase in hypospadias severity, 92.86% decrease in septation height, and 8.13% decrease in urethral length relative to those dosed on E14.5-16.5. PUO height showed a significant interaction between cumulative dose and day of exposure (n dam = 3, N pup = 73, Figure 6B Binomial regression was used for PUO incidence data, Poisson regression was used for PUO and septation data, and linear regressions was used for urethral length data. The penis by urethral length allometric relationship was used to correct urethral length for the length of the penis (urethral length scales as a power function of 0.34061 of penis length). Likelihood ratio tests were used to select the best model and a P-value < 0.05 was used to assess significant parameters in the model. Shaded envelopes are 95% confidence intervals derived from model estimates, ndam = 3, Npup = 151. All measurement data are presented as number of sections to obtain metric sizes multiple sections by 10 μm.
had an 89% increase in PUO height relative to those exposed on E14.5-16.5, whereas animals in the cumulative dose of 600 mg/kg and dosed on E13.5-16.5 showed a 12% increase relative to those dosed on E14.5-16.5.
Discussion
We found that blocking androgen signaling prior to the window within which penis development is most sensitive to antiandrogen exposure reduced nuclear AR localization and intensity (Figure 2) , and magnified the genital abnormalities induced by the model antiandrogen vinclozolin during the androgen sensitive window (Figures 3-6 ). Therefore, in the mouse, the genitalia are organized and made competent to respond to androgens prior to the critical window of genitalia development that defines the most hormonally sensitive period. We believe this potentiation occurs because the autoregulation between AR and circulating androgens is disorganized by early antiandrogen exposure. Early antiandrogen exposure, prior to the critical window of penis development or hormone-sensitive period, changed the dose response of each tissue and made later exposure more potent. For example, lower doses had stronger effects when the animals were exposed on E13.5 (Figures 4 and 5) . The increased potency associated with precritical window exposure occurs even when animals were exposed to the same total dose. Animals with a cumulative exposure of 300 mg/kg had a much stronger response when exposure began on E13.5 ( Figure 6 ) rather than when it began on E14.5. Indeed, the animals exposed to lower cumulative doses showed larger dosing day effects, but even at a total dose of 600 mg/kg beginning the dosing regime on day E13.5 consistently led to stronger effects relative to beginning dosing on E14.5 ( Figure 6 ). The effect of blocking the precritical window androgen signaling on E13.5 is not as strong at very high vinclozolin total concentrations likely because androgen signaling is strongly inhibited during the critical window of genitalia development (E15.5). Our correction of cumulative vinclozolin dose assumes that tissue concentrations of vinclozolin are the same. It is unknown how the single-day exposure difference affects vinclozolin and its metabolite concentrations within penis tissue. The idea that vinclozolin and it metabolites could be sequestered in the penis and potentiate penis defects by displacing androgens and continually binding AR is interesting and requires further investigation. Although the downstream molecular mechanisms causing the enhanced effects we found need to be investigated, our results demonstrate that tissues must be organized prior to morphological masculinization and that the effects of antiandrogens occur earlier than previously reported. Precritical window exposure to vinclozolin made the mouse fetus more sensitive to EDC exposure during the critical window within which the genitalia become sexually dimorphic. These data suggest that in humans susceptibility to developing hypospadias and the variation in severity of hypospadias cases could be partially explained by timing and dose of antiandrogen exposure.
Understanding the drivers of hypospadias severity
Our study showed that severity of hypospadias and several other structures involved in penis masculinization were more strongly affected when animals were exposed to antiandrogens on the day that androgen signaling is initiated (E13.5). Each day in development, different sets of signals and different regulatory networks must be organized so that the tissues are competent to respond to future signals. Timing and dosage differences in hormone or EDC exposure can result in different developmental outcomes. In early penis development, E13.5-15.5, morphology between male and female external genitalia remains nearly identical. Our data suggest that during this time androgen signaling is involved in setting up the cells within the urethral epithelium and mesenchyme of the penis to respond to hormonal cues during the critical window of genitalia. Although morphology is not different, molecular organization is likely sexually dimorphic at these early stages.
Developmental-endocrine signaling
The fact that vinclozolin exposure induced differences in nuclear AR density within the E14.5 genitalia relative to corn oil controls suggests that antiandrogen exposure diminished androgen-dependent Downloaded from https://academic.oup.com/biolreprod/article-abstract/99/3/639/4970759 by OUP site access user on 04 October 2018 upregulation (autoregulation) of AR in the genitalia at E13.5. The later changes in genitalia morphology that we documented suggest that this alteration in positive feedback propagates throughout development. The reduced feedback likely reduced the total AR concentrations and altered the ability of androgens to compete with vinclozolin for AR-binding sites. In other words, animals with less AR (e.g. first dosed on E13.5) suffered stronger competitive interactions between vinclozolin (and its metabolites) and androgens for AR. This had profound effects, as individuals exposed beginning on E14.5 required higher vinclozolin exposure to induce similar severities relative to individuals exposed on E13.5 (Figures 4 and 5) . Similar autoregulation of AR has been reported in the brain where testosterone exposure increased the density of AR in several different areas of the brain [37] .
Classically, adult studies have found that blocking androgen signaling results in increased AR levels in several masculine tissues (testis, prostate, brain). In development, we do not observe this, as negative feedback is typically required for homeostasis and not the formation of new organs [38] . Therefore, developing hypotheses about fetal responses based on information gleaned from adults will be inefficient and potentially faulty, as negative feedback regulation must develop before it can function. We show that in the fetal genitalia AR inhibition reduces the quantity of AR and exacerbates the antiandrogen induced alterations within the external genitalia. This antiandrogen-dependent decrease of AR is also found in the Wolffian ducts in fetal rats. For example, flutamide and linuron (antiandrogens) exposure reduced the amount of ARs within the epithelium of the developing ducts [39, 40] . Sexual dimorphic development cumulates in divergent phenotypes but where the morphological outcome lies on the spectrum of masculinity to femininity is dependent on timing and dosage of hormone signaling. Positive feedback loops have been identified to cause divergence and induce a bistable state leading to two distinct phenotypes [38] . Here we showed that penis development is likely driven by positive feedback of androgen signaling, and early disruption of that feedback results in more severe penis abnormalities. It is likely that other sexually dimorphic organs require similar, positive feedback between androgens and the AR.
Relevance to human health
Many reproductive defects, especially in males, have drastically increased over the past 50 years, which is largely thought to be due to the increased prevalence of environmental EDCs [18, [41] [42] [43] [44] [45] [46] . For example, sperm counts are currently decreasing and have declined by 50%-60% in Western men since 1973 [47] . These declines are coincident with environmental factors such as EDC exposure [2, 48, 49] . In fact, decreased sperm count is commonly associated with birth defects such as cryptorchidism and hypospadias, which suggests that it shares a common prenatal etiology with these reproductive disorders [47, 50] .
Hypospadias, a birth defect of the penis, increased in incidence by 200% between the years 1970 and 1990, and now occurs 1% of boys [51] in Colorado and Tennessee, as well as those born to military families [52] . In a recent surveillance study, hypospadias was the most common birth defect in 19 (61%) of 31 states surveyed [52] . In addition to the general increase in hypospadias incidence, severe cases have increased at a faster rate than milder cases [51] suggesting that the general increase is not driven by better reporting of cases that were commonly missed in the past.
Hypospadias occurs because the urethral folds do not close properly, which causes the urethral opening to occur ventrally along the shaft of the penis rather than at the distal tip. The severity of hypospadias depends on the position of the urethral meatus along the length of the penis, with proximal openings being more severe [26] . Severe cases of hypospadias result in ambiguous genitalia and in the past led to sexual reassignment surgery for the child [53] . Corrective penile surgery is an extremely difficult procedure due to different tissue types and the effects of scar tissue on penis function [54] . Both sexual reassignment and penile reconstruction surgeries place stress on both the babies and their families. Patients with hypospadias have lower self-esteem, and can suffer from difficulty urinating and pain during sexual intercourse [55] . Finding the developmental window that organizes future masculinization is essential because it can explain differences in hypospadias severity in human populations. If we know when the fetus is sensitive, we can advise mothers to be especially vigilant about environmental exposures during those times.
Conclusion
In the mouse model early exposure to the antiandrogenic EDC, vinclozolin affected penis development and overall masculinization of the penis. Early antiandrogen exposure affected the distribution of AR in the penis, and potentiated further endocrine disruption in the genitalia to additional antiandrogen. Ultimately, the interaction of dosing time, exposure concentration, and genetics must be understood in order to build a synthetic understanding of the origins of hypospadias and what drives its severity. This synthetic understanding will aid development of preventative therapies for environmentally induced hypospadias.
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